MapLight Therapeutics Initiates Initial Public Offering to Enhance Patient Care MapLight Therapeutics has filed for an initial public offering to boost its operations targeting CNS disorders, aiming to enhance patient care. This IPO marks a significant step in its mission.

MapLight Therapeutics Initiates Initial Public Offering to Enhance Patient Care #USA #NASDAQ #San_Francisco #MapLight_Therapeutics #ML-007C-MA

MapLight Therapeutics Secures $372.5 Million in Series D Financing Round to Drive CNS Innovations MapLight Therapeutics has raised $372.5 million in Series D funding, co-led by Forbion and Goldman Sachs, to advance its CNS therapies and focus on schizophrenia and Alzheimer's.

MapLight Therapeutics Secures $372.5 Million in Series D Financing Round to Drive CNS Innovations #United_States #Redwood_City #MapLight_Therapeutics #Alzheimer’s_Disease #Series_D_Funding

MapLight Therapeutics Launches Phase 2 Study for ML-007C-MA Targeting Schizophrenia Symptoms MapLight Therapeutics has begun its Phase 2 trial of ML-007C-MA, a novel treatment for schizophrenia, focusing on efficacy, safety, and tolerability.

MapLight Therapeutics Launches Phase 2 Study for ML-007C-MA Targeting Schizophrenia Symptoms #United_States #Redwood_City #MapLight_Therapeutics #schizophrenia #ML-007C-MA

MapLight Therapeutics Reports Phase 1 Trial Results for Innovative Treatment of Schizophrenia and Alzheimer's Psychosis MapLight Therapeutics reveals promising outcomes from the Phase 1 trial of ML-007/PAC, targeting schizophrenia and Alzheimer's disease psychosis. Plans for Phase 2 are set for 2025.

MapLight Therapeutics Reports Phase 1 Trial Results for Innovative Treatment of Schizophrenia and Alzheimer's Psychosis #United_States #San_Francisco #Alzheimer's_Disease #MapLight_Therapeutics #schizophrenia